Look out Alex­ion, Roche breaks out the de­tails on its ri­val rare CNS drug

Months af­ter Alex­ion scored the first-ever ap­proval for pa­tients with neu­romyelitis op­ti­ca spec­trum dis­or­der (NM­SOD) — re­searchers at Roche have come out with de­tailed da­ta on their ri­val ex­per­i­men­tal drug satral­izum­ab for use in the rare cen­tral ner­vous sys­tem dis­or­der.

The 95-pa­tient study dubbed SAkuraS­tar test­ed satral­izum­ab against a place­bo. Da­ta showed satral­izum­ab monother­a­py con­ferred a 55% re­duc­tion in the risk of re­laps­es com­pared to place­bo in the over­all pop­u­la­tion, rep­re­sen­ta­tive of NMOSD pa­tients (p=0.0184). In the over­all satral­izum­ab-treat­ed pop­u­la­tion, 76.1% were re­lapse-free at 48 weeks, and 72.1% re­lapse-free at 96 weeks, ver­sus 61.9% and 51.2% with place­bo, re­spec­tive­ly.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER